Lanoxin

Digoxin, the active ingredient in Lanoxin, is a cardiac glycoside presented as an intravenous solution for injection use. It is employed to control heart rate in atrial fibrillation and flutter and to improve contractility in patients with heart failure.

GNH USA supplies Lanoxin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Digoxin is a cardiac glycoside used to manage rhythm disorders and heart failure.

- Atrial fibrillation: Controls ventricular rate by slowing atrioventricular nodal conduction. - Atrial flutter: Reduces rapid atrial activity and helps maintain sinus rhythm. - Heart failure: Increases myocardial contractility, improving cardiac output and symptoms.

Digoxin may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes after dosing. - Diarrhea: loose stools, often transient. - Fatigue: generalized tiredness. - Blurred vision: visual disturbances, sometimes with a yellow‑green tint. - Headache: mild cranial discomfort.

Serious or Rare Side Effects: - Cardiac arrhythmias: potentially fatal rhythm disturbances. - Severe bradycardia: markedly reduced heart rate. - Heart block: impaired electrical conduction. - Hyperkalemia: elevated serum potassium levels. - Pulmonary edema: fluid accumulation in lungs. - Anaphylactic reaction: rare but severe hypersensitivity.

When using digoxin, careful monitoring and patient assessment are essential.

- Serum level monitoring: Check digoxin concentrations regularly to avoid toxicity. - Renal function assessment: Adjust dosing in patients with impaired kidney function. - Electrolyte balance: Correct hypokalemia, hypomagnesemia, and hypercalcemia before therapy. - Pregnancy safety: Use only if potential benefit justifies potential fetal risk (Category C). - Contraindications: Avoid in patients with ventricular arrhythmias or advanced AV block. - Store at controlled room temperature: Keep in original packaging, protect from moisture and light.

Digoxin interacts with several medicines that can alter its plasma concentration or cardiac effects.

Major Interactions (Avoid): - Amiodarone: Increases digoxin levels, raising toxicity risk. - Quinidine: Potentiates digoxin's effects on conduction. - Verapamil: Enhances digoxin concentration and AV‑node slowing. - Diltiazem: Similar effect as verapamil, may cause bradyarrhythmias. - Rifampin: Decreases digoxin levels, reducing efficacy.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): May cause electrolyte disturbances that predispose to toxicity. - ACE inhibitors: Can increase serum potassium, affecting cardiac rhythm. - Beta‑blockers: Additive bradycardic effect, requiring rate monitoring.